Phuong Dang

Safety and efficacy of imatinib cessation for CML patients with stable undetectable minimal residual disease: results from the TWISTER study

David M. Ross, Susan Branford, John F. Seymour et al. · Blood · 2013 · 706 citations

Medicine, Immunology, Pharmacotherapy +11

OCT-1–mediated influx is a key determinant of the intracellular uptake of imatinib but not nilotinib (AMN107): reduced OCT-1 activity is the cause of low in vitro sensitivity to imatinib

Deborah L. White, Verity A Saunders, Phuong Dang et al. · Blood · 2006 · 432 citations · Full text

Life Sciences, Cell Biology, Pharmacology +6

Most CML patients who have a suboptimal response to imatinib have low OCT-1 activity: higher doses of imatinib may overcome the negative impact of low OCT-1 activity

Deborah L. White, Verity A Saunders, Phuong Dang et al. · Blood · 2007 · 331 citations

Medicine, Hematology, Pharmacology +2

Dasatinib Cellular Uptake and Efflux in Chronic Myeloid Leukemia Cells: Therapeutic Implications

Devendra Hiwase, Verity A Saunders, D. Hewett et al. · Clinical Cancer Research · 2008 · 218 citations

Medicine, Oncology, Pharmacology +14

Functional Activity of the OCT-1 Protein Is Predictive of Long-Term Outcome in Patients With Chronic-Phase Chronic Myeloid Leukemia Treated With Imatinib

Deborah L. White, Phuong Dang, Jane R. Engler et al. · Journal of Clinical Oncology · 2010 · 183 citations

Medicine, Hematology, Pharmacology +11